SunRegen Healthcare is a late stage preclinical biotechnology company that is pioneering the development of novel small molecule therapeutics for the treatment of neurodegenerative conditions of the eye. Many of these conditions are significantly unmet, with patients suffering loss of vision and potentially blindness. Our lead indication is focused to Retinitis Pigmentosa, a rare, orphan retinal disease with few treatment options.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Small molecule SBC003
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):